Multimeric Biotherapeutics, Inc.
("Multimeric")
"Unlocking the potential of the TNF SuperFamily Ligands"

Multimeric Biotherapeutics, Inc. receives an exclusive license to all animal health and reagent uses of its patented multimeric TNF superfamily ligands

December 22, 2011, La Jolla, CA –Multimeric Biotherapeutics, Inc. (Multimeric), an early stage biotech company based in San Diego, announces its exclusive license to all veterinary and reagent uses of its platform technology for producing TNF superfamily ligands (TNFSFs) as highly active multimeric, many-trimer proteins. This technology was invented by Multimeric's scientific founder, Richard S. Kornbluth, MD, PhD, when he was a professor at the University of California San Diego (UCSD). His UCSD patents, now exclusively licensed to Multimeric, have been granted in the U.S., Europe, and Australia, and are patent-pending in Canada.

The animal health uses of multimeric TNFSFs include vaccines and cancer immunotherapy for companion animals, and vaccines for the livestock industry. The global veterinary vaccine market is projected to reach $5.6 billion by 2015, according to a recent report from Global Industry Analysts, Inc. In laboratory animals, Multimeric's MegaCD40L™ has been shown to be an effective immunological adjuvant for anti-viral vaccines and its UltraCD40L™ has been shown to be an effective immunotherapy for cancer. Multimeric seeks to partner these uses with established companies in the veterinary field.

From its newly amended UCSD license, Multimeric has also gained exclusive rights to all reagent sales of the MegaLigands™ in the U.S. and Australia (where patents have issued), and Canada (where the application is patent-pending). It has also gained exclusive rights to the UltraLigands™ in the U.S., Europe, and Australia (where patents have issued), and Canada (where the application is patent-pending).

About the MegaLigands™: The term MegaLigands™ refers to 2-trimer forms of the TNFSF ligands produced by fusing the extracellular domains of any of the 19 members of the TNF SuperFamily with a scaffold protein consisting of the body of ACRP30 (adiponectin). The following molecules are currently sold by third parties as purified proteins for laboratory use: MegaCD40L™; MegaTNF™; MegaOX40L™; and MegaAPRIL™. MegaCD40L™ in particular has been used extensively by academic investigators as a vaccine adjuvant and cancer immunotherapy agent.

About the UltraLigands™: The term UltraLigands™ refers to 4-trimer forms of the TNFSF ligands produced by fusing the extracellular domains of any of the 19 members of the TNF SuperFamily with a scaffold protein consisting of the body of surfactant protein D (SP-D). UltraCD40L™ has been shown to be a powerful adjuvant for DNA vaccines as well as an effective cancer immunotherapy in mouse models. A recently published study in the journal *Vaccine* demonstrated the versatility of this platform technology by reporting applications for the following UltraLigands™ as adjuvants for DNA vaccines: UltraCD40L™; UltraGITRL™; Ultra4-1BBL™; UltraOX40L™; UltraRANKL™; UltraLIGHT™; UltraCD70™; and UltraBAFF™.

About Multimeric: Multimeric Biotherapeutics, Inc., a Delaware C corporation, was spun out of technology developed by Dr. Richard Kornbluth when he was at the University of California San Diego. Multimeric's lead products include immunotherapy protocols for cancer and vaccines against chronic viral infections. The company is privately held and is supported by its founders, angel investors, and NIH grants. It has offices in La Jolla, CA and laboratories at the San Diego Science Center in San Diego, CA. For more information, please refer to www.multimericbio.com

Multimeric Biotherapeutics, Inc.
5580 La Jolla Blvd. Ste 76
La Jolla, CA 92037-7651

Email: info{at}multimericbio.com
Web: www.multimericbio.com